Home › Companies › Trevi Therapeutics, Inc. › 2025-2026

Trevi Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Trevi Therapeutics, Inc.’s Form 8-K, filed 2026-06-04 (Item 5.07 on EDGAR). Page generated 02 October 2026.

5Reported items
193Asset managers
1,084Fund votes
2026-06-03Meeting date

Proxy season: 2024-2025 2025-2026

Explore Trevi Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Trevi Therapeutics, Inc.

These tallies are Trevi Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Trevi Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-03
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Proposal 1	81,567,765	--	--	18,635,726	14,140,404	Majority: yes
Proposal 2: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified.	114,001,970	223,323	118,602	--	--	Majority: yes
Proposal 3: The compensation of the Company's named executive officers was approved, on an advisory basis.	98,119,461	1,982,126	101,904	--	14,140,404	Majority: yes
Proposal 4: The A&R 2019 Plan was approved.	98,140,470	1,961,030	101,991	--	14,140,404	Majority: yes
Proposal 5: The Amendment to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares was approved.	110,453,620	3,872,599	17,676	--	--	Majority: yes

Source: Trevi Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-04 — read the filing on EDGAR.

How asset managers voted at the Trevi Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 193 asset managers that disclosed a Trevi Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Trevi Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 98,119,461AGAINST: 1,982,126

Trevi Therapeutics, Inc.’s own tally for this item (“Proposal 3: The compensation of the Company's named executive officers was approved, on an advisory basis.”): 98,119,461 for, 1,982,126 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 128,411,048 outstanding shares: 76% for, 2% against (78% of the company cast a for/against vote).

The 193 asset managers below cast 99% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 99%

FOR: 98.5%AGAINST: 1.4%ABSTAIN: 0.1%

Largest asset managers voting on “APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at Trevi Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	17,776,808	0	For
NEA Management Company, LLC	13,225,026	0	For
Frazier Life Sciences Management, L.P.	9,939,547	0	For
Vanguard	6,737,627	4	For
BlackRock	5,372,431	25,528	For
Vivo Capital, LLC	5,094,668	0	For
AllianceBernstein	4,138,752	0	For
VIKING GLOBAL INVESTORS LP	3,198,644	0	For
MPM BioImpact LLC	2,930,957	0	For
Wellington	2,772,637	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,675,847	0	For
MUTUAL FUND SERIES TRUST	2,646,276	0	For
Artia Global Partners LP	2,013,602	0	For
Siren, L.L.C.	1,786,867	0	For
State Street	1,706,731	17,508	For
Charles Schwab	1,704,321	0	For
PICTET ASSET MANAGEMENT SA	1,530,435	0	For
Octagon Capital Advisors LP	1,485,000	0	For
ORBIMED ADVISORS LLC	1,403,717	0	For
Rubric Capital Management LP	1,288,918	0	For
NAN FUNG TRINITY (HK) Ltd	1,142,950	0	For
Vestal Point Capital, LP	1,113,973	0	For
Logos Global Management LP	966,371	0	For
EMERALD ADVISERS, LLC	873,193	0	For
Principal	804,021	0	For

Showing the 25 largest of 193 asset managers. See all 193 in the interactive database.

2. APPROVAL OF THE TREVI THERAPEUTICS, INC. AMENDED AND RESTATED 2019 STOCK INCENTIVE PLAN.

COMPENSATIONMajority of the votes cast: yes

98% Majority: yes · of votes cast

FOR 98%

FOR: 98,140,470AGAINST: 1,961,030

Trevi Therapeutics, Inc.’s own tally for this item (“Proposal 4: The A&R 2019 Plan was approved.”): 98,140,470 for, 1,961,030 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 128,411,048 outstanding shares: 76% for, 2% against (78% of the company cast a for/against vote).

The 55 asset managers below cast 99.9% of the shares they voted on this item FOR (39,646,743 for, 25 against).

FOR 99.8%

FOR: 39,646,743 (99.8%)AGAINST: 25 (0.0%)ABSTAIN: 78,615 (0.2%)

Largest asset managers voting on “APPROVAL OF THE TREVI THERAPEUTICS, INC. AMENDED AND RESTATED 2019 STOCK INCENTIVE PLAN.” at Trevi Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
NEA Management Company, LLC	13,225,026	0	0	For
Fidelity	9,723,168	0	0	For
Vanguard	5,885,699	4	0	For
MUTUAL FUND SERIES TRUST	2,646,276	0	0	For
BlackRock	2,093,710	0	0	For
AllianceBernstein	1,503,499	0	0	For
Charles Schwab	840,997	0	0	For
Principal	804,021	0	0	For
RBB FUND, INC.	756,714	0	0	For
Hartford	233,747	0	0	For
Equitable	233,282	0	0	For
Allspring	222,155	0	0	For
OPTIMUM FUND TRUST	170,067	0	0	For
QUANTITATIVE MASTER SERIES LLC	148,121	0	0	For
State Street	125,206	21	0	For
Lincoln Financial	108,812	0	0	For
Brighthouse	29,636	0	78,615	Abstain
Empower	89,530	0	0	For
TIAA	70,732	0	0	For
Invesco	69,371	0	0	For
Simplify Exchange Traded Funds	65,412	0	0	For
AMG Funds I	53,566	0	0	For
AIG/SunAmerica	49,804	0	0	For
Goldman Sachs	49,500	0	0	For
MASTER INVESTMENT PORTFOLIO	48,119	0	0	For

Showing the 25 largest of 55 asset managers. See all 55 in the interactive database.

3. APPROVAL OF AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 200,000,000 SHARES TO 400,000,000 SHARES.

CAPITAL STRUCTUREMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 110,453,620AGAINST: 3,872,599

Trevi Therapeutics, Inc.’s own tally for this item (“Proposal 5: The Amendment to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares was approved.”): 110,453,620 for, 3,872,599 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 128,411,048 outstanding shares: 86% for, 3% against (89% of the company cast a for/against vote).

The 54 asset managers below cast 95% of the shares they voted on this item FOR (25,214,882 for, 1,296,356 against).

FOR 95%

FOR: 25,214,882 (95.1%)AGAINST: 1,296,356 (4.9%)

Largest asset managers voting on “APPROVAL OF AN AMENDMENT TO OUR RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO INCREASE THE NUMBER OF A” at Trevi Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	9,723,168	0	For
Vanguard	5,877,013	8,690	For
MUTUAL FUND SERIES TRUST	2,646,276	0	For
BlackRock	2,093,710	0	For
AllianceBernstein	1,503,499	0	For
Charles Schwab	840,997	0	For
Principal	352,376	451,645	Against
RBB FUND, INC.	0	756,714	Against
Hartford	233,747	0	For
Equitable	233,282	0	For
Allspring	222,155	0	For
OPTIMUM FUND TRUST	170,067	0	For
QUANTITATIVE MASTER SERIES LLC	148,121	0	For
State Street	125,141	86	For
Lincoln Financial	108,812	0	For
Brighthouse	29,636	78,615	Against
Empower	89,530	0	For
TIAA	70,732	0	For
Invesco	69,371	0	For
Simplify Exchange Traded Funds	65,412	0	For
AMG Funds I	53,566	0	For
AIG/SunAmerica	49,804	0	For
Goldman Sachs	49,500	0	For
MASTER INVESTMENT PORTFOLIO	48,119	0	For
Global X	44,565	0	For

Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.

4. Election of one Class I director to our Board of Directors, to serve until the 2029 Annual Meeting of Stockholders: Michael Heffernan

DIRECTOR ELECTIONS

Combines 5 wordings of this item as funds reported it.

100% fund support · no official result

FOR 84%ABSTAIN 16%

The 54 asset managers below cast 100% of the shares they voted on this item FOR (22,289,085 for, 0 against).

FOR: 22,289,085 (84.1%)ABSTAIN: 4,222,153 (15.9%)

Largest asset managers voting on “Election of one Class I director to our Board of Directors, to serve until the 2029 Annual Meeting of Stockhol” at Trevi Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Fidelity	9,723,168	0	For
Vanguard	5,885,667	36	For
MUTUAL FUND SERIES TRUST	2,622,306	23,970	For
BlackRock	2,093,710	0	For
AllianceBernstein	0	1,503,499	Abstain
Charles Schwab	840,997	0	For
Principal	0	804,021	Abstain
RBB FUND, INC.	0	756,714	Abstain
Hartford	0	233,747	Abstain
Equitable	152,842	80,440	For
Allspring	0	222,155	Abstain
OPTIMUM FUND TRUST	170,067	0	For
QUANTITATIVE MASTER SERIES LLC	148,121	0	For
State Street	185	125,042	Abstain
Lincoln Financial	0	108,812	Abstain
Brighthouse	0	108,251	Abstain
Empower	89,530	0	For
TIAA	70,732	0	For
Invesco	69,371	0	For
Simplify Exchange Traded Funds	65,412	0	For
AMG Funds I	53,566	0	For
AIG/SunAmerica	0	49,804	Abstain
Goldman Sachs	28,890	20,610	For
MASTER INVESTMENT PORTFOLIO	48,119	0	For
Global X	44,565	0	For

Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.

5. RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 114,001,970AGAINST: 223,323

Trevi Therapeutics, Inc.’s own tally for this item (“Proposal 2: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified.”): 114,001,970 for, 223,323 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 128,411,048 outstanding shares: 89% for, 0.2% against (89% of the company cast a for/against vote).

The 54 asset managers below cast 99.9% of the shares they voted on this item FOR (26,432,603 for, 21 against).

FOR 99.7%

FOR: 26,432,603 (99.7%)AGAINST: 21 (0.0%)ABSTAIN: 78,615 (0.3%)

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ” at Trevi Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	9,723,168	0	0	For
Vanguard	5,885,703	0	0	For
MUTUAL FUND SERIES TRUST	2,646,276	0	0	For
BlackRock	2,093,710	0	0	For
AllianceBernstein	1,503,499	0	0	For
Charles Schwab	840,997	0	0	For
Principal	804,021	0	0	For
RBB FUND, INC.	756,714	0	0	For
Hartford	233,747	0	0	For
Equitable	233,282	0	0	For
Allspring	222,155	0	0	For
OPTIMUM FUND TRUST	170,067	0	0	For
QUANTITATIVE MASTER SERIES LLC	148,121	0	0	For
State Street	125,206	21	0	For
Lincoln Financial	108,812	0	0	For
Brighthouse	29,636	0	78,615	Abstain
Empower	89,530	0	0	For
TIAA	70,732	0	0	For
Invesco	69,371	0	0	For
Simplify Exchange Traded Funds	65,412	0	0	For
AMG Funds I	53,566	0	0	For
AIG/SunAmerica	49,804	0	0	For
Goldman Sachs	49,500	0	0	For
MASTER INVESTMENT PORTFOLIO	48,119	0	0	For
Global X	44,565	0	0	For

Showing the 25 largest of 54 asset managers. See all 54 in the interactive database.

Largest Trevi Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Trevi Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 128,411,048 shares outstanding at the time of that meeting.

Top Trevi Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	13.84%
2	NEA Management Company, LLC	10.30%
3	Frazier Life Sciences Management, L.P.	7.74%
4	Vanguard	5.25%
5	BlackRock	4.20%
6	Vivo Capital, LLC	3.97%
7	AllianceBernstein	3.22%
8	VIKING GLOBAL INVESTORS LP	2.49%
9	MPM BioImpact LLC	2.28%
10	Wellington	2.16%

Reported Trevi Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Trevi Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Edward Mathers	11.88%	DEF14A
Entities affiliated with New Enterprise Associates	11.74%	DEF14A
New Enterprise Associates 16, L.P.	11.74%	13D
Entities affiliated with Frazier Life Sciences	10.23%	DEF14A
BlackRock	7.97%	13F
FMR (Fidelity)	6.26%	13F
Entities affiliated with BlackRock, Inc.	5.30%	DEF14A
Entities affiliated with FMR LLC	5.06%	DEF14A
Vanguard Group	5.01%	13F
Wellington Management	4.04%	13F

Percentages above are of 128,411,048 shares outstanding, as reported by Trevi Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Trevi Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Trevi Therapeutics, Inc.'s shareholder meeting held 2026-06-03, in the 2025-2026 proxy season, 193 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,084 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Trevi Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-04.

Trevi Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).